DSP-3077

N/A

Report date: 2026/04/18 20:00:19

Base Information

Drug NameDSP-3077

Drug Alias NameDSP-3077

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Somatic cell > Retinal cell therapyCell and gene therapy > Cell therapy > Source of cells > iPSC-derived

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsRetinitis Pigmentosa

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesSumitomo Pharma America Inc

China Registration ClassN/A

Develop Information

Active CompaniesSumitomo Pharma America Inc

Inactive CompaniesN/A

Active IndicationsRetinitis Pigmentosa

Inactive IndicationsN/A

Other Information

ATC CodeN/A